Stem Point Capital LP Portfolio Holdings

Stem Point Capital LP

  • $334 Billion
  • Q3 2024

Stem Point Capital LP has filed its 13F form on November 13, 2024 for Q3 2024 where it was disclosed a total value porftolio of $334 Billion distributed in 58 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Syndax Pharmaceuticals Inc with a value of $33.3B, Roivant Sciences Ltd. with a value of $32B, Merus N.V. with a value of $21B, Immunovant, Inc. with a value of $19.1B, and Arcutis Biotherapeutics, Inc. with a value of $16.5B.

Examining the 13F form we can see an decrease of $6.26B in the current position value, from $340B to 334B.

Stem Point Capital LP is based out at New York, NY

Below you can find more details about Stem Point Capital LP portfolio as well as his latest detailed transactions.

Portfolio value $334 Billion
Healthcare: $277 Billion

Stock Holdings Table Market Cap. of $10 Billions to $200 Billions

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History
$125B
$14.2 Billion 4.26% of portfolio
275,303
Q3 2024 New
$16.6B
$8.56 Billion 2.56% of portfolio
129,490
Q3 2024 New
$10B
$1.88 Billion 0.56% of portfolio
15,014
Q3 2024 New

Summary

  • Portfolio
  • No. of Stocks 58
  • Current Value $334 Billion
  • Prior Value $340 Billion
  • Filing
  • Period Q3 2024
  • Filing Date November 13, 2024
  • Form Type 13F-HR
  • Activity in Q3 2024
  • New Purchases 21 stocks
  • Additional Purchases 10 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 17 stocks
Track This Portfolio

Track Stem Point Capital LP Portfolio

Follow Stem Point Capital LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stem Point Capital LP, based on Form 13F filings with the SEC.

News

Stay updated on Stem Point Capital LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email